LIVER FIBROSIS TREATMENT MARKET ANALYSIS

Liver Fibrosis Treatment Market, by Treatment Type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and Others), by Condition (Chronic Liver Diseases, Hepatitis C, and Nonalcoholic Steatohepatitis), by Distribution Channel (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI2320
Pages :168
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

High cost required for drug development of liver disease treatment procedure

Global Liver Fibrosis Treatment Market: Restraint

The major factors that hinder growth of the global liver fibrosis treatment market include high cost required for drug development of liver disease treatment procedure. For instance, in January 2019, according to data published by PubMed, the race in the pharmaceutical industry to develop drugs to treat a form of fatty liver disease, industry experts estimate the global market for these new drugs is $35 billion. The U.S. spends US$5 billion annually in health-care costs related to the disease, which include chemotherapy, transplants, tests and hospitalizations, as reported by the Center for Disease Analysis.